Table 3.
Biochemical Relapse-Free Survival
| RP | 3D-CRT | I-125 | EBRT+Seeds | |||
|---|---|---|---|---|---|---|
| D’Amico38 | Zelefsky92 | Grimm15 | Sylvester93 | |||
| (HUP)(B&W) | (MSKCC) | (Seattle) | (Seattle) | |||
| Risk | 5-yr BRFS | 10-yr BRFS | 10-yr BRFS | 10-yr BRFS | ||
| Group | (DRG) | (DRG) | (SRG) | (SRG) | (SRG) | (DRG) |
| Low | 85% | 83% | 83% | 87% | 85% | 84 |
| Intermediate | 65% | 50% | 50% | 76% | 77% | 90% |
| High | 32% | 28% | 42% | — | 47% | 46% |
RP, radical prostatectomy; HUP, Hospital of the University of Pennsylvania; B & W Brigham and Women’s Hospital; BRFS biochemical relapse-free survival; DRG, D’Amico risk grouping; 3D-CRT, three-dimensional conformal radiotherapy; MSKCC, Memorial Sloan-Kettering Cancer Center; SRG, standard MSKCC risk grouping; I-125, iodine-125; EBRT, external beam radiotherapy.